Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. But with promising early results from a phase 3 study in certain ...

Merck (NYSE:MRK) said a Phase 3 study of its drug Keytruda in the treatment of a certain type of ovarian cancer met its primary endpoint of progression-free survival, but not its secondary ...

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.

Keytruda is not approved to treat ovarian cancer. Sunday, Merck announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin in combination with ...

Merck (NYSE:MRK) announced Thursday that its bestselling therapy, Keytruda, as part of a combination regimen, reached the primary endpoint in a Phase 3 trial for a certain type of ovarian cancer.

Merck’s Keytruda shows promise in ovarian cancer trial. RAHWAY, N.J. – Merck & Co., Inc., a global healthcare leader, announced positive results from its Phase 3 KEYNOTE-B96 trial, which could ...

Merck's KEYLYNK-001 trial showed Keytruda and Lynparza improved progression-free survival in BRCA non-mutated ovarian cancer patients. In the waveLINE-007 trial, zilovertamab vedotin with R-CHP ...

Merck (MRK) reported mixed Phase 3 results for its drug Keytruda in combination with Lynparza and chemotherapy in the treatment of a certain type of ovarian cancer. Read more here.

On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with ...